Bacillus sp. VT-712

Bacillus sp. VT-712 in Patients with Intestinal Cancer

Given previous evidence that gut microbes contribute to cancer development, the presence of Bacillus sp. VT-712 in patients with duodenal cancer may indicate a role for this organism in cancer’s progression. This organism is a novel species that was isolated from the intestine of a patient with intestinal cancer. Genetic analyses indicated that Bacillus sp. VT-712 harbors numerous antibiotic resistance genes, as well as various toxin-encoding genes, including hemolysin, nucleases and numerous peptidases. In addition Bacillus sp. VT-712 is a spore-forming bacterium and produced spores are resistant to antibiotics. Additional studies are therefore warranted to examine the role of Bacillus sp. VT-712 in gastrointestinal diseases.

In future research, we intend to determine the prevalence of Bacillus sp. VT-712 among different cancer patient groups, as well as in healthy individuals and in persons suffering from other microbiota-associated diseases.


Tetz G, Tetz V. 2016. Complete genome sequence of a novel Bacillus sp. VT 712 strain isolated from the duodenum of a patient with intestinal cancer. Genome Announc 4(4):e00786-16. doi:10.1128/genomeA.00786-16.

Read article

Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer.

Publication Type JournalArticle
Authors George Tetz
Victor Tetz
Abstract We report here the complete genome sequence of the spore-forming Bacillus sp. strain VT 712 isolated from the duodenum of a patient with intestinal cancer. The genome is 3,921,583 bp, with 37.9% GC content. It contains 3,768 predicted protein-coding genes for multidrug resistance transporters, virulence factors, and daunorubicin resistance.
Year of Publication 2016
Journal Genomeannouncements
DOI 10.1128/genomeA.00786-16